Detalhe da pesquisa
1.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
2.
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.
Blood
; 142(19): 1633-1646, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390336
3.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood
; 141(14): 1685-1690, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608320
4.
Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.
Eur J Nucl Med Mol Imaging
; 51(8): 2293-2307, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456971
5.
Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models.
J Magn Reson Imaging
; 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733369
6.
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma.
Eur J Haematol
; 2024 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38898589
7.
Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients.
Haematologica
; 108(12): 3308-3320, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381752
8.
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
BMC Cancer
; 23(1): 1132, 2023 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990162
9.
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
Hematol Oncol
; 41(3): 453-462, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36680428
10.
A precision-based exercise program for patients with multiple myeloma.
Eur J Haematol
; 111(6): 930-937, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37727991
11.
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Transfus Med Hemother
; 50(5): 371-381, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37936633
12.
Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
Br J Haematol
; 199(1): 65-75, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608264
13.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
14.
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
Haematologica
; 107(8): 1891-1901, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045690
15.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 379(19): 1811-1822, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403938
16.
Venetoclax in myeloma: to B, or not to B.
Blood
; 143(1): 4-5, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175678
17.
Novel immunotherapies in multiple myeloma - chances and challenges.
Haematologica
; 106(10): 2555-2565, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196164
18.
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
BMC Cancer
; 21(1): 993, 2021 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34488662
19.
B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Int J Cancer
; 147(8): 2029-2041, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32270481
20.
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Br J Haematol
; 190(2): 189-197, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32163180